Solving Synthesis Challenges: Small Molecule CTDMO Strategies

Ross Bemowski oversees the analytical development for new API products coming out of the API R&D group located in Madison, WI. He is also the technical lead for Chetosensar™ technology platform. Prior to this, he was an analytical development scientist supporting the CDMO offering from our company.

He studied synthetic organometallic chemistry and received his Ph.D. from the University of Iowa.

Matt Dodge has 14 years of experience in client-facing roles within the pharmaceutical CDMO/CRO space. Currently, he is the head of client project management for our Madison/Verona and Sheboygan sites. He obtained his Ph.D. in organic chemistry from the University of Wisconsin-Madison.

Angela Masino has been in the pharmaceutical manufacturing industry for 18 years. Currently, she is the Head of Quality at our site in Madison, Wisconsin. In this position she is focused on leading process improvement initiatives with emphasis on quality, operational excellence, efficiency and productivity. Angela previously held quality positions supporting both large and start-up companies at CellScript, Mentor, and Johnson & Johnson. She strives to instill a “Quality Always” mindset among all employees regardless of position or role. Angela holds a bachelor’s degree in chemistry from the University of Wisconsin-Whitewater.

Jason Modest has been in the pharmaceutical industry for 25 years and is the director of the manufacturing, science, and technology department at the Madison/Verona, WI site. He leads the technical transfer and validation teams and provides life cycle management for commercial programs. Transitioning into technical operations positions in brand, generic, and the CDMO space has allowed for a comprehensive understanding of what is required to successfully move early-phase development programs to commercial launch. Jason holds a B.S. in biochemistry from Fort Lewis College.

Kyle has extensive cross-functional expertise in science, operations and business development and is currently head of sales of the ADC and small molecule business. He started his career at Merck in 2001, applying his educational background in chemistry to various roles as a manufacturing supervisor, senior project manager, and senior business development manager. His experience and background inform his work in his current role as part of the synthesis and ADC CDMO business.

John Stevens joined the company in 2004 and held a variety of positions in our HPAPI facility, focusing on project leadership in the scale up and first-time GMP production of HPAPIs and complex APIs and lead the site MSAT team for 3 years. In 2019 he took on a role as a field marketing senior specialist for the actives & formulation team. Currently,  John supports the life science services commercial team in the small molecule modality. John received his M.S. in chemistry from the University of Wisconsin.